Maxi Potassium channel beta/KCNMB1 peptide (ab5023)
Key features and details
- Purity: > 70% HPLC
- Suitable for: Blocking
製品の詳細
-
製品名
Maxi Potassium channel beta/KCNMB1 peptide -
精製度
> 70 % HPLC.
Peptides are analyzed by Reverse-Phase HPLC (RP-HPLC) in order to determine purity. Identities are confirmed by MALDI-MS. -
Animal free
No -
由来
Synthetic
特性
Our Abpromise guarantee covers the use of ab5023 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Blocking
-
製品の状態
Lyophilized -
備考
This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and human Maxi K+ beta, catalog ab5023. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~ 70-fold) for competitive inhibition of antibody-protein binding reactions.
This product was previously labelled as Maxi Potassium channel beta
-
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped at 4°C. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
再構成>95% pure, lyophilized synthetic peptide. Reconstitute with 0.1 ml of distilled water.
関連情報
-
別名
- BK channel beta subunit
- BK channel subunit beta 1
- BK channel subunit beta-1
see all -
機能
Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate. -
組織特異性
Abundantly expressed in smooth muscle. Low levels of expression in most other tissues. Within the brain, relatively high levels found in hippocampus and corpus callosum. -
配列類似性
Belongs to the KCNMB (TC 8.A.14.1) family. KCNMB1 subfamily. -
翻訳後修飾
N-glycosylated. -
細胞内局在
Membrane. - Information by UniProt
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (3)
ab5023 は 3 報の論文で使用されています。
- Sun Q et al. LncRNA-MALAT1 regulates proliferation and apoptosis of ovarian cancer cells by targeting miR-503-5p. Onco Targets Ther 12:6297-6307 (2019). PubMed: 31496733
- Bhattarai Y et al. Western blot analysis of BK channel ß1-subunit expression should be interpreted cautiously when using commercially available antibodies. Physiol Rep 2: (2014). PubMed: 25355855
- Navarro-Antolín J et al. Decreased expression of maxi-K+ channel beta1-subunit and altered vasoregulation in hypoxia. Circulation 112:1309-15 (2005). PubMed: 16116057
